Rhumatologie

Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in refractory heel enthesitis related to spondyloarthritis: Results of a double blind placebo controlled study (HEEL)

Arthritis&Rheum.2009;60(10 suppl):S669(P1786)

M Dougados, B Combe, J Braun, R Landewé, J Sibilia, A Cantagrel, V Leblanc, I Logeart

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of disease activity for patients with axial spondyloarthritis
Rhumatologie

Impact of disease activity for patients with axial spondyloarthritis

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis
Rhumatologie

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France